NASDAQ:KURA

Kura Oncology Stock Insider Trading

Healthcare > Biotechnology

Buy KURA

*Your capital is at risk

$8.66

-0.315 (-3.51%)

At Close: Jun 03, 2026

Kura Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 31.90. In total, the insiders bought 3.99M and sold 291.61K KURA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	31.90
● Buy	3.99M shares
● Sell	291.61K shares
57% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence May 21, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 31.9. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 02, 2026 Buy	Common Stock A-Award	Leoni Mollie Chief Medical Officer	Officer	50 000 Value: $516.8K
Jan 02, 2026 Buy	Common Stock A-Award	Doyle Thomas James SVP, Finance & Accounting	Officer	21 250 Value: $219.6K
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Leoni Mollie Chief Medical Officer	Officer	100 000 Value: $1.03M
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Doyle Thomas James SVP, Finance & Accounting	Officer	42 500 Value: $439.2K
Jan 02, 2026 Buy	Common Stock A-Award	Ford Kathleen Chief Operating Officer	C-Suite Officer	50 000 Value: $516.8K
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Ford Kathleen Chief Operating Officer	C-Suite Officer	100 000 Value: $1.03M
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Burrows Francis Chief Scientific Officer	Officer	185 000 Value: $1.91M
Jan 02, 2026 Buy	Common Stock A-Award	Powl Brian T. Chief Commercial Officer	Officer	50 000 Value: $516.8K
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Powl Brian T. Chief Commercial Officer	Officer	100 000 Value: $1.03M
Jan 02, 2026 Buy	Common Stock A-Award	Bair Teresa Brophy Chief Legal Officer	Officer	50 000 Value: $516.8K
Jan 02, 2026 Buy	Option to purchase common stock A-Award	Bair Teresa Brophy Chief Legal Officer	Officer	100 000 Value: $1.03M
Dec 18, 2025 Buy	Common Stock M-Exempt	Burrows Francis Chief Scientific Officer	Officer	35 000 Value: $168.0K
Dec 18, 2025 Sell	Common Stock S-Sale	Burrows Francis Chief Scientific Officer	Officer	23 726 Value: $231.9K
Dec 18, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Burrows Francis Chief Scientific Officer	Officer	35 000 Value: $168.0K
Dec 09, 2025 Buy	Common Stock M-Exempt	Hasnain Faheem Director	Director	10 000 Value: $31.2K
Dec 09, 2025 Sell	Common Stock S-Sale	Hasnain Faheem Director	Director	10 000 Value: $109.8K
Nov 14, 2025 Sell	Common Stock S-Sale	Bair Teresa Brophy Chief Legal Officer	Officer	8 804 Value: $98.4K
Nov 14, 2025 Sell	Common Stock S-Sale	Powl Brian T. Chief Commercial Officer	Officer	8 887 Value: $99.3K
Nov 14, 2025 Sell	Common Stock S-Sale	Leoni Mollie Chief Medical Officer	Officer	15 485 Value: $173.1K
Nov 14, 2025 Sell	Common Stock S-Sale	Doyle Thomas James SVP, Finance & Accounting	Officer	4 539 Value: $50.7K
Nov 14, 2025 Sell	Common Stock S-Sale	Ford Kathleen Chief Operating Officer	C-Suite Officer	6 902 Value: $77.1K
Nov 13, 2025 Buy	Common Stock A-Award	Bair Teresa Brophy Chief Legal Officer	Officer	48 900 Value: $522.3K
Nov 13, 2025 Buy	Common Stock A-Award	Wilson Troy Edward President And CEO	CEO / President	182 500 Value: $1.95M
Nov 13, 2025 Buy	Common Stock A-Award	Powl Brian T. Chief Commercial Officer	Officer	48 900 Value: $522.3K
Nov 13, 2025 Buy	Common Stock A-Award	Leoni Mollie Chief Medical Officer	Officer	82 500 Value: $881.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KURA ONCOLOGY

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi...

Read Full Profile Here